2022-RA-905-ESGO Mismatch repair deficiency is not applicable as biomarker in cervical cancer, yet M...
2022-RA-905-ESGO Mismatch repair deficiency is not applicable as biomarker in cervical cancer, yet MSH-2 has strong prognostic value
About this item
Full title
Author / Creator
Publisher
Kidlington: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
Introduction/BackgroundAlthough early detected cervical cancer is associated with good survival, prognosis for late-stage disease is poor and treatment options are sparse. Mismatch-repair (MMR) deficiency has surfaced as a predictor of immune checkpoint inhibitor responses in several cancer types, but its value in cervical cancer remains unclear. T...
Alternative Titles
Full title
2022-RA-905-ESGO Mismatch repair deficiency is not applicable as biomarker in cervical cancer, yet MSH-2 has strong prognostic value
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2728883216
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2728883216
Other Identifiers
ISSN
1048-891X
E-ISSN
1525-1438
DOI
10.1136/ijgc-2022-ESGO.68
